S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in
NASDAQ:HOLX

Hologic Competitors

$76.34
+0.64 (+0.85 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$74.41
Now: $76.34
$76.59
50-Day Range
$71.74
MA: $75.35
$80.49
52-Week Range
$26.49
Now: $76.34
$81.80
Volume1.55 million shs
Average Volume1.67 million shs
Market Capitalization$19.62 billion
P/E Ratio18.18
Dividend YieldN/A
Beta1.27

Competitors

Hologic (NASDAQ:HOLX) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying HOLX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Hologic, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Hologic (NASDAQ:HOLX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Profitability

This table compares Abbott Laboratories and Hologic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Hologic29.53%45.24%15.53%

Risk & Volatility

Abbott Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Hologic has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Abbott Laboratories and Hologic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories121302.75
Hologic05802.62

Abbott Laboratories currently has a consensus price target of $115.6875, indicating a potential upside of 0.84%. Hologic has a consensus price target of $79.5625, indicating a potential upside of 4.22%. Given Hologic's higher probable upside, analysts plainly believe Hologic is more favorable than Abbott Laboratories.

Earnings & Valuation

This table compares Abbott Laboratories and Hologic's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.37$3.69 billion$3.2435.41
Hologic$3.78 billion5.20$1.12 billion$3.9819.18

Abbott Laboratories has higher revenue and earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. Comparatively, 92.4% of Hologic shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 1.0% of Hologic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Medtronic (NYSE:MDT) and Hologic (NASDAQ:HOLX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Medtronic and Hologic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.44$4.79 billion$4.5925.47
Hologic$3.78 billion5.20$1.12 billion$3.9819.18

Medtronic has higher revenue and earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Hologic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.69%9.71%5.30%
Hologic29.53%45.24%15.53%

Institutional & Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. Comparatively, 92.4% of Hologic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 1.0% of Hologic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Medtronic has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Hologic has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Medtronic and Hologic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic032012.92
Hologic05802.62

Medtronic currently has a consensus price target of $122.2963, indicating a potential upside of 4.62%. Hologic has a consensus price target of $79.5625, indicating a potential upside of 4.22%. Given Medtronic's stronger consensus rating and higher probable upside, equities analysts clearly believe Medtronic is more favorable than Hologic.

Summary

Medtronic beats Hologic on 9 of the 15 factors compared between the two stocks.

Hologic (NASDAQ:HOLX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Hologic and Stryker, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hologic05802.62
Stryker271412.58

Hologic presently has a consensus target price of $79.5625, indicating a potential upside of 4.22%. Stryker has a consensus target price of $227.4783, indicating a potential downside of 5.04%. Given Hologic's stronger consensus rating and higher possible upside, equities analysts plainly believe Hologic is more favorable than Stryker.

Profitability

This table compares Hologic and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hologic29.53%45.24%15.53%
Stryker12.35%20.94%8.77%

Risk & Volatility

Hologic has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Valuation & Earnings

This table compares Hologic and Stryker's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hologic$3.78 billion5.20$1.12 billion$3.9819.18
Stryker$14.88 billion6.05$2.08 billion$8.2629.00

Stryker has higher revenue and earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.4% of Hologic shares are owned by institutional investors. Comparatively, 71.5% of Stryker shares are owned by institutional investors. 1.0% of Hologic shares are owned by insiders. Comparatively, 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Stryker beats Hologic on 8 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Hologic (NASDAQ:HOLX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of recent ratings for Intuitive Surgical and Hologic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381002.33
Hologic05802.62

Intuitive Surgical currently has a consensus target price of $736.0588, indicating a potential downside of 2.12%. Hologic has a consensus target price of $79.5625, indicating a potential upside of 4.22%. Given Hologic's stronger consensus rating and higher possible upside, analysts clearly believe Hologic is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Hologic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Hologic29.53%45.24%15.53%

Volatility & Risk

Intuitive Surgical has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Hologic has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Valuation and Earnings

This table compares Intuitive Surgical and Hologic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.74$1.38 billion$9.9575.58
Hologic$3.78 billion5.20$1.12 billion$3.9819.18

Intuitive Surgical has higher revenue and earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

86.5% of Intuitive Surgical shares are held by institutional investors. Comparatively, 92.4% of Hologic shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 1.0% of Hologic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Becton, Dickinson and (NYSE:BDX) and Hologic (NASDAQ:HOLX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

83.2% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 92.4% of Hologic shares are held by institutional investors. 0.8% of Becton, Dickinson and shares are held by company insiders. Comparatively, 1.0% of Hologic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Becton, Dickinson and and Hologic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07702.50
Hologic05802.62

Becton, Dickinson and currently has a consensus price target of $279.6667, indicating a potential upside of 7.46%. Hologic has a consensus price target of $79.5625, indicating a potential upside of 4.22%. Given Becton, Dickinson and's higher possible upside, analysts clearly believe Becton, Dickinson and is more favorable than Hologic.

Profitability

This table compares Becton, Dickinson and and Hologic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Hologic29.53%45.24%15.53%

Volatility & Risk

Becton, Dickinson and has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Hologic has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares Becton, Dickinson and and Hologic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion4.42$874 million$10.2025.51
Hologic$3.78 billion5.20$1.12 billion$3.9819.18

Hologic has lower revenue, but higher earnings than Becton, Dickinson and. Hologic is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Hologic beats Becton, Dickinson and on 10 of the 14 factors compared between the two stocks.

Hologic (NASDAQ:HOLX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Insider & Institutional Ownership

92.4% of Hologic shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 1.0% of Hologic shares are held by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Hologic and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hologic29.53%45.24%15.53%
Edwards Lifesciences18.18%29.00%18.10%

Valuation and Earnings

This table compares Hologic and Edwards Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hologic$3.78 billion5.20$1.12 billion$3.9819.18
Edwards Lifesciences$4.35 billion12.31$1.05 billion$1.8646.18

Hologic has higher earnings, but lower revenue than Edwards Lifesciences. Hologic is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Hologic and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hologic05802.62
Edwards Lifesciences271202.48

Hologic currently has a consensus price target of $79.5625, indicating a potential upside of 4.22%. Edwards Lifesciences has a consensus price target of $90.8704, indicating a potential upside of 5.80%. Given Edwards Lifesciences' higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Hologic.

Risk & Volatility

Hologic has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.


Hologic Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.4$114.72+1.6%$203.33 billion$31.90 billion60.70Upcoming Earnings
Medtronic logo
MDT
Medtronic
2.7$116.90+0.3%$157.35 billion$28.91 billion44.62
Stryker logo
SYK
Stryker
2.0$239.55+0.2%$90.02 billion$14.88 billion51.96Upcoming Earnings
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$752.01+1.1%$88.40 billion$4.48 billion85.65Earnings Announcement
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$260.24+0.6%$75.69 billion$17.12 billion95.33Dividend Announcement
News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$85.89+0.4%$53.53 billion$4.35 billion68.71Upcoming Earnings
Boston Scientific logo
BSX
Boston Scientific
2.2$36.78+0.7%$52.67 billion$10.74 billion14.09
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$489.21+0.7%$41.73 billion$2.41 billion85.23Upcoming Earnings
Baxter International logo
BAX
Baxter International
2.3$80.10+0.7%$40.92 billion$11.36 billion45.51
DexCom logo
DXCM
DexCom
1.9$376.39+1.7%$36.14 billion$1.48 billion155.53Insider Selling
ResMed logo
RMD
ResMed
1.4$221.68+2.8%$32.12 billion$2.96 billion47.57Upcoming Earnings
Insulet logo
PODD
Insulet
1.3$288.91+0.5%$19.05 billion$738.20 million656.63
Teleflex logo
TFX
Teleflex
2.0$382.14+1.1%$17.80 billion$2.60 billion49.18
STERIS logo
STE
STERIS
2.1$190.41+0.9%$16.25 billion$3.03 billion38.62Upcoming Earnings
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.33+0.1%$16.02 billion$3.17 billion59.84
Abiomed logo
ABMD
Abiomed
1.5$348.32+0.1%$15.74 billion$840.88 million76.55Upcoming Earnings
Masimo logo
MASI
Masimo
1.4$257.09+2.6%$14.15 billion$937.84 million66.78
Hill-Rom logo
HRC
Hill-Rom
2.0$101.16+1.7%$6.71 billion$2.88 billion30.47
Globus Medical logo
GMED
Globus Medical
1.4$64.44+1.4%$6.36 billion$785.37 million70.04
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$69.36+0.1%$5.85 billion$1.52 billion103.52
NuVasive logo
NUVA
NuVasive
1.5$56.80+0.2%$2.91 billion$1.17 billion-258.18
AtriCure logo
ATRC
AtriCure
1.3$58.30+1.3%$2.62 billion$230.81 million-50.70
Integer logo
ITGR
Integer
2.3$78.15+1.2%$2.57 billion$1.26 billion35.52
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.3$46.51+0.3%$1.87 billion$236.54 million-70.47
Alphatec logo
ATEC
Alphatec
0.8$14.92+0.7%$1.17 billion$113.43 million-13.56
CryoLife logo
CRY
CryoLife
1.5$24.96+1.2%$969.87 million$276.22 million-65.68
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$44.94+2.2%$868.77 million$459.95 million37.45
AngioDynamics logo
ANGO
AngioDynamics
1.6$18.55+1.9%$704.04 million$264.16 million-4.15
Surmodics logo
SRDX
Surmodics
1.5$46.33+1.0%$633.89 million$94.86 million579.13News Coverage
Accuray logo
ARAY
Accuray
2.2$5.08+0.6%$463.67 million$382.93 million36.29Upcoming Earnings
Invacare logo
IVC
Invacare
1.6$9.92+0.1%$341.43 million$927.96 million-8.06
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.46+2.7%$136.62 million$61.30 million-3.40
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.